Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational drug-device combination product for magnetic resonance imaging (MRI), notes the news release on 25 May by the Oxford Biomedical Research Centre concerning a study carried out in longer-term lung damage after COVID-19.

The study was published online in the Journal Radiology (https://pubs.rsna.org/doi/10.1148/radiol.2021210033). This preliminary research determined that hyperpolarised xenon MRI scans had found abnormalities in the lungs of some COVID-19 patients more than three months - and in some cases, nine months - after leaving hospital, when other clinical measurements were normal. Polarean had supplied Oxford University Hospitals Trust with an earlier research model that was used for the study and are working towards providing a new state-of-the-art polariser for further research.

Principal Investigator Prof Fergus Gleeson, Professor of Radiology at the University of Oxford and Consultant Radiologist at Oxford University Hospitals NHS Foundation Trust, said: "Many COVID-19 patients are still experiencing breathlessness several months after being discharged from hospital, despite their CT scans indicating that their lungs are functioning normally. Our follow-up scans using hyperpolarised xenon MRI have found that abnormalities not normally visible on regular scans are indeed present, and these abnormalities are preventing oxygen getting into the bloodstream as it should in all parts of the lungs."

The full news release can be viewed here: https://oxfordbrc.nihr.ac.uk/study-confirms-longer-term-lung-damage-after-covid-19/

Enquiries:


Polarean Imaging plc		www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer		Via Walbrook PR
Jonathan Allis, Chairman

Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)			+44 (0)20 7710 7600
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)
Nick Adams / Fred Walsh (Corporate Broking)

Walbrook PR	Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Anna Dunphy		Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUVVKRAOUVUAR

AI Terminal

POLAREAN IMAGING PLC

7850_rns_2021-05-26_8a64539a-0309-4b65-af98-7beba008c0ac.html

More from POLAREAN IMAGING PLC

Talk to a Data Expert